ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

08 Jan 2026 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

15 Dec 2025 17:39:45 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

10 Nov 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

06 Nov 2025 16:05:03 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

03 Nov 2025 09:04:20 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

30 Oct 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

27 Aug 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

13 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

06 Aug 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

01 Aug 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

01 Jun 2025 10:45:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

23 May 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

22 May 2025 17:17:55 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

13 May 2025 16:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

06 May 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 10:12:13 By Nasdaq GlobeNewswire

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

07 Apr 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

13 Mar 2025 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

03 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in March Investor Conference

26 Feb 2025 08:30:00 By Nasdaq GlobeNewswire